"Virginia Oncology Associates is an oncology and hematology practice of physicians, specializing in the diagnosis and treatment of cancer and blood disorders. With locations spanning the southeast region of Virginia and Northeastern North Carolina, we are able to extend services and treatments to patients, including medical oncology, radiation oncology, gynecologic oncology, hematology, diagnostics, clinical research, stem cell transplantation, genetic counseling, and psychosocial oncology."

During the past decade, Virginia Oncology Associates conducted 7 clinical trials. In the 10-year time frame, 7 clinical trials started and 4 clinical trials were completed, i.e. on average, 57.1% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 3 clinical trials were completed. i.e. 75% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Virginia Oncology Associates" #1 sponsor was "Pfizer" with 4 trials, followed by "Gilead Sciences" with 3 trials sponsored, "Alliance for Clinical Trials in Oncology" with 1 trials sponsored, "Ascenta Therapeutics" with 1 trials sponsored and "Biotheranostics, Inc." with 1 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Virginia Oncology Associates" #1 collaborator was "Astellas Pharma Inc" with 1 trials as a collaborator, "Life Technologies, Inc." with 1 trials as a collaborator, "Medivation LLC, a wholly owned subsidiary of Pfizer Inc." with 1 trials as a collaborator, "Merck Sharp & Dohme LLC" with 1 trials as a collaborator and "National Cancer Institute (NCI)" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "Virginia Oncology Associates" are "Triple Negative Breast Cancer" (3 trials), "Breast Cancer" (2 trials), "Metastatic Breast Cancer" (2 trials), "Castration-Resistant Prostate Cancer" (1 trials) and "Colorectal Adenocarcinoma" (1 trials). Many other conditions were trialed in "Virginia Oncology Associates" in a lesser frequency.

Most popular intervention types in "Virginia Oncology Associates" are "Drug" (11 trials), "Diagnostic Test" (1 trials), "Dietary Supplement" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Paclitaxel" (4 trials), "Gemcitabine" (3 trials), "Carboplatin" (2 trials), "Placebo" (2 trials) and "Sacituzumab Govitecan-hziy" (2 trials). Other intervention names were less common.

The vast majority of trials in "Virginia Oncology Associates" are 9 trials for "All" genders, 3 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Virginia Oncology Associates". undefined are not yet recruiting, 4 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 6 completed trials in Virginia Oncology Associates, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Virginia Oncology Associates, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 9 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".